Cipla Limited (CIPLA)
ISIN: INE059A01026 Industry: Drug Manufacturers—General Sector: Healthcare Website
930.65
-18.65(-1.96%)

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. Cipla Limited has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19; partnership with Karwa Ltd. for the commercialization of antibody detection kits for COVID-19; partnership with the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19; licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.

Pricing Updates

TODAY'S HIGH

950

TODAY'S LOW

928.5

52 WEEK HIGH

1083

52 WEEK LOW

850

Major Holders

% of Shares Held by
All Insider

35.31%

% of Shares Held by
Institutions

32.47%

% of Float Held by
Institutions

50.20%

Number of Institutions
Holding Shares

204

Company Overview

MARKET CAP

75158.08 Cr.

ETERPRISE VALUE

73798.87 Cr.

NO. OF SHARES

80.69 Cr.

BOOK VALUE

258.321

DIV. YIELD

5%

DEBT

1055.78 Cr.

GROSS PROFIT

13267.74 Cr.

CASH

4123.45 Cr.

REVENUE

21763.34 Cr.

REVENUE/SHARE

269.799

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments152.57 Cr.-1258.63 Cr.1176.69 Cr.-1068.37 Cr.
Change To Liabilities362.29 Cr.203.05 Cr.487.28 Cr.-152.51 Cr.
Total cashflows from Investing Activities-1871.88 Cr.-2387.18 Cr.104.04 Cr.-1668.68 Cr.
Net Borrowings-1098.33 Cr.-1167.85 Cr.-1760.02 Cr.-60.25 Cr.
Total Cash from Financing Activities-1599.79 Cr.-1329.90 Cr.-2948.82 Cr.-348.72 Cr.
Other Liabilities0000
Total Assets7 Lakhs5 Lakhs11 Lakhs12 Lakhs
Net Income2516.75 Cr.2404.87 Cr.1546.52 Cr.1527.70 Cr.
Change in Cash-132.32 Cr.50.91 Cr.234.02 Cr.-345.10 Cr.
Effect of Exchange Rate13.45 Cr.12.79 Cr.10.35 Cr.-18.85 Cr.
Total Cash from Operating Activities3325.90 Cr.3755.20 Cr.3068.45 Cr.1691.14 Cr.
Depreciation1051.95 Cr.963.81 Cr.1056.40 Cr.1056.51 Cr.
Other Cashflows from Investing Activities-1358.46 Cr.-339.76 Cr.-88.23 Cr.82.60 Cr.
Dividends Paid-403.35 Cr.-403.35 Cr.-241.77 Cr.-241.57 Cr.
Change to Inventory-621.11 Cr.-254.32 Cr.-331.55 Cr.103.84 Cr.
Change to Account Receivables81.36 Cr.422.93 Cr.217.26 Cr.-1014.87 Cr.
Other Cashflows from Financing Activities-98.18 Cr.-162.10 Cr.-624.65 Cr.-47.02 Cr.
Change to Net Income-65.34 Cr.-24.45 Cr.48.99 Cr.129.83 Cr.
Capital Expenditures-544.11 Cr.-629.66 Cr.-572.77 Cr.-360.08 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax3480.45 Cr.3277.27 Cr.2130.72 Cr.2061.97 Cr.
Minority Interest275.69 Cr.259.06 Cr.294.28 Cr.331.97 Cr.
Net Income3500.83 Cr.3265.51 Cr.2119.98 Cr.2041.26 Cr.
Selling General Administrative3529.91 Cr.4128.12 Cr.3869.37 Cr.3741.54 Cr.
Gross Profit13267.74 Cr.11615.53 Cr.10932.49 Cr.10394.71 Cr.
Ebit3500.83 Cr.3265.51 Cr.2119.98 Cr.2041.26 Cr.
Operating Income3500.83 Cr.3265.51 Cr.2119.98 Cr.2041.26 Cr.
Other Operating Expenses5185.05 Cr.3218.78 Cr.3843.19 Cr.3515.08 Cr.
Interest Expense-106.35 Cr.-152.98 Cr.-189.23 Cr.-163.77 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense933.80 Cr.888.76 Cr.631.20 Cr.569.53 Cr.
Total Revenue21763.34 Cr.19121.90 Cr.17080.53 Cr.16323.23 Cr.
Total Operating Expenses18262.51 Cr.15856.39 Cr.14960.55 Cr.14281.97 Cr.
Cost of Revenue8495.60 Cr.7506.37 Cr.6148.04 Cr.5928.52 Cr.
Total Other Income Expense Net-20.38 Cr.11.76 Cr.10.74 Cr.20.71 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.2546.65 Cr.2388.51 Cr.1499.52 Cr.1492.44 Cr.
Net Income Applicable to Common Shares2516.75 Cr.2404.87 Cr.1546.52 Cr.1527.70 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets1702.86 Cr.1828.26 Cr.1900.07 Cr.1908.15 Cr.
Capital Surplus01613.31 Cr.1602.03 Cr.1574.59 Cr.
Total Liabilities5983.74 Cr.6566.30 Cr.7605.28 Cr.8619.07 Cr.
Stock Holder Equity20841.69 Cr.18326.53 Cr.15763 Cr.15012.28 Cr.
Minority Interest275.69 Cr.259.06 Cr.294.28 Cr.331.97 Cr.
Other Liabilities1923.85 Cr.1133.58 Cr.986.13 Cr.807.31 Cr.
Total Assets27101.12 Cr.25151.89 Cr.23662.56 Cr.23963.32 Cr.
Common Stock161.36 Cr.161.29 Cr.161.25 Cr.161.14 Cr.
Retained Earnings016681.62 Cr.14260.50 Cr.13393.93 Cr.
Other Liabilities496.01 Cr.574.11 Cr.659.78 Cr.1017.49 Cr.
Good Will3137.93 Cr.3007.29 Cr.2934 Cr.2869.14 Cr.
Treasury Stock20680.33 Cr.-129.69 Cr.-260.78 Cr.-117.38 Cr.
Other Assets1585.15 Cr.1062.77 Cr.996.80 Cr.773.58 Cr.
Cash1928.48 Cr.793.29 Cr.742.38 Cr.508.36 Cr.
Current Liabilities4913.21 Cr.4591.55 Cr.4393.14 Cr.3771.51 Cr.
Long Term Asset Charges448.83 Cr.314.69 Cr.239.77 Cr.201.41 Cr.
Short Long Term Debt407.90 Cr.227.78 Cr.16.75 Cr.0
Other Stockholder Equity20680.33 Cr.-129.69 Cr.-260.78 Cr.-117.38 Cr.
Property Plant Equipment5608.72 Cr.5648.86 Cr.5673.35 Cr.5507.25 Cr.
Total Cur. Assets14710.83 Cr.13181.03 Cr.11703.84 Cr.12426.63 Cr.
Long Term Investments355.63 Cr.423.68 Cr.454.50 Cr.478.57 Cr.
Net Tangible Assets16000.90 Cr.13490.98 Cr.10928.93 Cr.10234.99 Cr.
Short Term Investments2194.97 Cr.670.36 Cr.250.08 Cr.100.81 Cr.
Net Receivables3428.01 Cr.3619.34 Cr.4226.07 Cr.4398.82 Cr.
Long Term Debt416.24 Cr.1202.75 Cr.2369.28 Cr.3830.07 Cr.
Inventory5350.24 Cr.4669.18 Cr.4377.60 Cr.3964.83 Cr.
Accounts Payable2508.10 Cr.2066.82 Cr.2281.81 Cr.1947.99 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account